Lincoln Pharma launches chewable vitamin C, zinc tablets
Jumping into the already-populated space of vitamin tablets, pharma player Lincoln Pharmaceuticals Ltd on Thursday announced the launch of chewable V30-07-2020
30-07-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press / Media Release titled 'Lincoln Pharmaceuticals Limited launches Vitamin C+ Zinc Tablets to boost immunity in the fight against CoVID-19'.30-07-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosure Of Related Party Transactions
Disclosure of related party transactions pursuant to regulation 23 (9) of SEBI LODR, 2015, on consolidated basis for the half year ended 31st March, 2020.23-07-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholding for the Period Ended June 30, 2020
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here17-07-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter Ended June 30, 2020.13-07-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer13-07-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window
Pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 read with SEBI [Prohibition of Insider Trading] [Amendment] Regulations, 2018 and Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the Company it is informed that the Trading Window for dealing in securities of the Company shall remain closed from July 01, 2020 till Forty Eight Hours after the declaration of Un-Audited Financial Results of the Company for the Quarter Ended on June 30, 2020. During the aforesaid period when the Trading Window is closed, Directors, Senior Management Personnel, Promoter and Promoter Group of the Company and its subsidiaries including their Immediate Relatives and other Connected Persons shall not trade in securities of the Company. The date of the Board Meeting of the Company for Declaration of Un-Audited Financial Results for the Quarter Ended June 30, 2020 will be intimated to the Stock Exchange in due course separately.30-06-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 08, 2019, please find enclosed Secretarial Compliance Report for the year ended on March 31, 2020.25-06-2020
Lincoln Pharma Q4 profit rises 29% to 9 crore
Ahmedabad-based pharma player Lincoln Pharmaceuticals Limited posted a standalone net profit of 9.23 crore for the fourth quarter ended March 2020,25-06-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Audited Financial Results For The Quarter And Year Ended March 31, 2020.
To considered and approved the Audited Financial Results of the Company (Standalone and Consolidated) for the Quarter and Year Ended on March 31, 2020, along with the Reports of Auditors thereon. Pursuant to Regulation 33 (3) (d) of SEBI LODR Regulations, we hereby declare that the Statutory Auditors have issued Audit Report with Un-Modified Opinion on the Audited Financial Results (Standalone and Consolidated) of the Company for the Year Ended March 31, 2020. The copies of the said Declaration, Financial Results and Auditors Reports are enclosed herewith.25-06-2020